DeCure for Small intestinal neuroendocrine tumor G1
DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for small intestinal neuroendocrine tumor G1 — screening already-approved drugs against its 47-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSmall intestinal neuroendocrine tumor G1 maps to a 47-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for small intestinal neuroendocrine tumor g1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
transforming growth factor beta receptor 2 (TGFBR2) — TGFBR2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 6-methoxypyridin-3-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5QIN · 1.57 Å · ligand N-{4-[3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide (J2V). Experimental structure, not a prediction.
What the evidence adds up to
Small intestinal neuroendocrine tumor G1 is a rare malignancy of putative enterochromaffin cell origin, and the most common tumour of the small intestine. The abstracts provided contain no clinical trial data, no survival figures, and no response rates for any drug in this specific tumour type. One 2014 review mentions that gastroenteropancreatic neuroendocrine tumours remain difficult to treat with conventional cytotoxic regimens, and that a symposium highlighted abstracts on a novel targeted means of treatment, but no drug name, outcome, or patient number is given. A 2015 Chinese-language abstract states that the main treatments are surgery and comprehensive therapy including chemotherapy and targeted therapy, again without naming any drug or reporting results.
A 2022 lineage-tracing study in mice found that tissue- and cell-specific properties of enterochromaffin cells, such as rapid turnover and homeostatic dedifferentiation, affect the fate of tumourigenesis toward nonendocrine adenocarcinoma, but this is basic biology, not a treatment trial. A 2021 case report describes a long-term complete response in a single patient with metastatic poorly-differentiated neuroendocrine rectal carcinoma (not small intestinal G1) after a multimodal approach; it explicitly notes that radiotherapy has been demonstrated inefficacious and that chemotherapy remains the treatment of choice for poorly differentiated NECs, but this does not apply to G1 tumours.
No abstract provides evidence for any drug in small intestinal neuroendocrine tumor G1. What is missing is any prospective trial, any randomised comparison, any biomarker for patient stratification, and any funding for drug-repurposing studies in this specific grade and site.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
World Journal of Gastroenterology · 2010 · 23 citations · open access
Pathologic research update of colorectal neuroendocrine tumors
AbstractColorectal neuroendocrine tumors (NETs) originate from neuroendocrine cells in the intestinal tract, and represent a small area within oncology, but one which has provided increasing new data during the past years. Although the World Health Organization has determined clinical and histological features to predict prognosis for such tumors, they may not be valid on an individual basis. We aim to give an overview of the recent findings with regard to pathology, molecular genetics and diagnosis of NETs.
AbstractGastroenteropancreatic neuroendocrine tumors are a heterogeneous group of carcinomas that remain difficult to treat with conventional cytotoxic regimens. The 2014 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium brought us new insights into the management of gastroenteropancreatic neuroendocrine tumors. The focus of this review will serve to highlight specific Abstracts (#268 and #273) that help shed light on a novel, targeted means of treating gastroenteropancreatic neuroendocrine tumors.
American Journal of Physiology-Gastrointestinal and Liver Physiology · 2022 · 4 citations · open access
Tissue- and cell-specific properties of enterochromaffin cells affect the fate of tumorigenesis toward nonendocrine adenocarcinoma of the small intestine
AbstractSmall intestinal neuroendocrine tumors are of putative enterochromaffin (EC) cell origin and are the most common malignancy in the small intestine, followed by adenocarcinoma. However, the tumorigenesis of these tumor types remains poorly understood. The present lineage tracing studies showed that tissue- and cell-specific properties of EC cells such as rapid cell turnover and homeostatic dedifferentiation affect the fate and rate of tumorigenesis induced by genetic alterations toward a rare occurrence of adenocarcinoma.
Long Term Complete Response in Metastatic Poorly-Differentiated Neuroendocrine Rectal Carcinoma With Multimodal Approach: A Case Report
AbstractAims Neuroendocrine gastrointestinal tumors (NETs) are rare and they have different natural behavior. Surgery is the gold standard treatment in local disease while radiotherapy has been demonstrated inefficacy. Poorly differentiated neuroendocrine carcinomas (NECs) represent only 5–10 % among digestive NETS. Due to aggressive growth and rapid metastatic diffusion, early diagnosis and multidisciplinary approach are mandatory. The role of surgery and radiotherapy in this setting is still debated, chemotherapy approach instead remains the treatment of choice.
Management of Neuroendocrine Cancers of the Gastrointestinal Tract: Carcinoid Tumors
AbstractAbstract Moertel once described the effort to treat neuroendocrine tumors as an “odyssey in the land of small tumors.”1 Although relatively rare, carcinoid tumors are the most common neuroendocrine tumor of the gastrointestinal tract and often present with dramatic manifestations that range from asymptomatic hepatomegaly to flushing, diarrhea, asthma, pellagra, and carcinoid heart disease. These tumors are often indolent but resistant to chemotherapy. Successful treatment of these tumors requires an understanding of their natural history and biology and of the impact of the available treatments.
AbstractGastrointestinal neuroendocrine tumor (GI-NET) originates from peptide neurons and neuroendocrine cells in gastrointestinal tract, and secrets peptide hormones, leading to carcinoid syndrome which rarely happens in clinical practice. Because of the improvement of diagnostic method and understanding of this rare disease, the morbidity is rising in recent years. The main treatments of GI-NET are surgery and comprehensive therapy, consisting of chemotherapy and targeted therapy.
Key words:
Gastrointestinal tract; Neuroendocrine tumors; Diagnostic evaluation; Therapeutics
JOURNAL OF CLINICAL AND BIOMEDICAL SCIENCES · 2020 · 0 citations · open access
Synchronous presentation of gastrointestinal stromal tumor of stomach and neuroendocrine tumor of Jejunum as acute intestinal obstruction
AbstractNeuroendocrine tumors (NETs) arise from the diffuse components of the endocrine system A patient with jejunoileal NETs usually presents with vague abdominal complains which may progress to intestinal ob-struction. Gastrointestinal stromal tumors (GIST) are mesenchymal tumors arising from interstitial cell of Cajal or pacemaker cells. GIST is the most common mesenchymal tumor of the abdomen. We are here by reporting a rare synchronous tumor for awareness and better management of patents. Keywords: Synchronous, Gastrointestinal tumors, stomach, Jejunum, NETs.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
